Journal article
Efficacy of amisulpride in treating primary negative symptoms in first-episode psychosis: a pilot study
Brendan P Murphy, Antonia H Stuart, Darryl Wade, Sue Cotton, Patrick D McGorry
HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL | JOHN WILEY & SONS LTD | Published : 2006
DOI: 10.1002/hup.807
Abstract
OBJECTIVE: Negative symptoms are debilitating and associated with poor role functioning and reduced quality of life. There is a paucity of research on antipsychotic efficacy against the primary negative symptoms, particularly in first-episode psychosis (FEP). We undertook a prospective, open-label pilot trial to investigate the use of amisulpride in the treatment of young people with FEP characterised by primary negative symptoms. METHOD: Twelve male and two female first-episode patients with primary negative symptoms (aged 16-26) were commenced on low-dose amisulpride (mean 250 mg/day) and followed-up over a 6-month period. Primary outcome measures were the Scale for the Assessment of Negat..
View full abstract